JP2023529152A - コロナウイルス感染を含むウイルス感染を阻害するための物質および方法 - Google Patents

コロナウイルス感染を含むウイルス感染を阻害するための物質および方法 Download PDF

Info

Publication number
JP2023529152A
JP2023529152A JP2022574660A JP2022574660A JP2023529152A JP 2023529152 A JP2023529152 A JP 2023529152A JP 2022574660 A JP2022574660 A JP 2022574660A JP 2022574660 A JP2022574660 A JP 2022574660A JP 2023529152 A JP2023529152 A JP 2023529152A
Authority
JP
Japan
Prior art keywords
virus
seq
biofilm
qi611s
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2022574660A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023529152A5 (https=
Inventor
ニコラス ティー． モンスル
エバ エイ． バークス
フレデリック ティー． ベーム
ユ－シェン リャオ
Original Assignee
クオラム イノベーションズ リミテッド ライアビリティ カンパニー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by クオラム イノベーションズ リミテッド ライアビリティ カンパニー filed Critical クオラム イノベーションズ リミテッド ライアビリティ カンパニー
Publication of JP2023529152A publication Critical patent/JP2023529152A/ja
Publication of JP2023529152A5 publication Critical patent/JP2023529152A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/335—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Lactobacillus (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/225—Lactobacillus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2022574660A 2020-06-06 2021-06-07 コロナウイルス感染を含むウイルス感染を阻害するための物質および方法 Withdrawn JP2023529152A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063035733P 2020-06-06 2020-06-06
US63/035,733 2020-06-06
PCT/US2021/036104 WO2021248111A1 (en) 2020-06-06 2021-06-07 Materials and methods for inhibiting a viral infection, including a coronavirus infection

Publications (2)

Publication Number Publication Date
JP2023529152A true JP2023529152A (ja) 2023-07-07
JP2023529152A5 JP2023529152A5 (https=) 2024-06-11

Family

ID=78831585

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022574660A Withdrawn JP2023529152A (ja) 2020-06-06 2021-06-07 コロナウイルス感染を含むウイルス感染を阻害するための物質および方法

Country Status (11)

Country Link
US (2) US11826390B2 (https=)
EP (1) EP4161558A4 (https=)
JP (1) JP2023529152A (https=)
KR (1) KR20230025853A (https=)
CN (1) CN116133669A (https=)
AU (1) AU2021286002A1 (https=)
BR (1) BR112022024911A2 (https=)
CA (1) CA3180737A1 (https=)
IL (1) IL298401A (https=)
MX (1) MX2022015439A (https=)
WO (1) WO2021248111A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2022006163A (es) * 2019-11-26 2022-06-17 Quorum Innovations Llc Nuevas composiciones de barrera protectora y usos de las mismas.

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002951270A0 (en) * 2002-09-06 2002-09-19 Vri Biomedical Ltd Probiotic Bacterium and Methods of Use
WO2007040446A1 (en) 2005-10-06 2007-04-12 Probi Ab Use of lactobacillus for treatment of autoimmune diseases
BRPI0822997A2 (pt) * 2008-09-04 2015-06-23 Om Pharma Extratos imunomoduladores de bactérias lactobacillus e métodos para fabricação e uso dos mesmos
KR101378608B1 (ko) * 2011-04-13 2014-03-27 씨제이제일제당 (주) 바이러스 감염 억제 활성을 갖는 신규 분리한 락토바실러스 퍼멘텀 균주
DK3324986T3 (da) * 2015-07-20 2022-01-31 Quorum Innovations Llc Materialer og fremgangsmåder til forbedring af immunreaktioner og hud- og/eller slimhindebarrierefunktion
CA3176797A1 (en) * 2020-05-06 2021-11-11 Nicholas T. Monsul Novel protein, and therapeutic and cosmetic uses thereof

Also Published As

Publication number Publication date
US20230136276A1 (en) 2023-05-04
AU2021286002A1 (en) 2023-01-19
EP4161558A1 (en) 2023-04-12
BR112022024911A2 (pt) 2022-12-27
US20240075083A1 (en) 2024-03-07
KR20230025853A (ko) 2023-02-23
WO2021248111A1 (en) 2021-12-09
EP4161558A4 (en) 2024-06-19
IL298401A (en) 2023-01-01
CN116133669A (zh) 2023-05-16
MX2022015439A (es) 2023-03-22
CA3180737A1 (en) 2021-12-09
WO2021248111A9 (en) 2022-12-22
US11826390B2 (en) 2023-11-28

Similar Documents

Publication Publication Date Title
US20220380769A1 (en) Methods, compositions, and vaccines for treating a virus infection
US12048741B2 (en) Recombinant host cell with heterologous nucleic acids encoding SHREK proteins
RS62644B9 (sr) Terapija bakteriofagima
KR20180037185A (ko) 광범위의 항감염성 펩티드
CN106574251A (zh) 新颖噬菌体和包括其的组合物
WO2021194563A2 (en) Novel protective barrier compositions, and uses thereof
US20240075083A1 (en) Materials and methods for inhibiting a viral infection, including a coronavirus infection
KR102750010B1 (ko) 호흡기 바이러스 감염의 치료 또는 예방을 위한 수퍼옥시드 디스무타아제 활성을 갖는 폴리펩티드 및 세포외 소포체의 용도
US20250295748A1 (en) Treatment and prevention of viral infections
JPWO2004020635A1 (ja) バクテリオファージおよび細菌感染症治療剤
US20250025528A1 (en) Materials and methods for preventing or reducing toxicity to organophosphates and other toxic materials
KR102586836B1 (ko) 클로스트리디움 퍼프린젠스에 대한 특이적인 사멸능을 가지는 신규한 박테리오파지 및 이를 포함하는 항균 조성물
CN107794247A (zh) 一株痤疮丙酸杆菌噬菌体及其应用
CN118632705A (zh) 用于预防或减少有机磷酸酯和其他有毒材料的毒性的材料和方法
TWI394578B (zh) 抗菌蛋白之新用途
EP2011508B1 (en) Use of trap protein per se as active ingredient for manufacturing a medicament for the treatment of staphylococcus aureus infection
CN116763902B (zh) 抗冠状病毒脂肽在治疗和预防流行性感冒中的用途
JP5685562B2 (ja) らい菌による感染症を予防又は治療するためのワクチン、抗体及び医薬
JP5086633B2 (ja) 細胞内に侵入する能力を有するペプチド及び核酸、物質を細胞内に侵入させるための物質移送用剤及び物質移送方法、並びに、らい菌による感染症を予防又は治療するためのワクチン、抗体及び医薬
RU2773149C2 (ru) Композиции и способы для защиты от присутствующих в воздухе патогенов и раздражителей
Shesha Characterizing the Cytotoxicity of Pseudomonas aeruginosa PAO1 on Triple Negative Breast Cancer Cells
CN108059627A (zh) 一种抗结核杆菌化合物及其制备和应用

Legal Events

Date Code Title Description
RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20230919

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240531

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240531

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20250625

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20250625